ACR 173: APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2024-05-30
Current Status:
Passed
(2024-05-30: Chaptered by Secretary of State - Res. Chapter 71, Statutes of 2024.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
This measure would encourage each individual in the United States to become better informed and aware of kidney disease and APOL1-mediated kidney disease (AMKD). The measure would encourage people from or with ancestry from Western and Central Africa to consider genetic testing for apolipoprotein L1 (APOL1) gene mutations. The measure would designate the last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
This measure would encourage each individual in the United States to become better informed and aware of kidney disease and APOL1-mediated kidney disease (AMKD). The measure would encourage people from or with ancestry from Western and Central Africa to consider genetic testing for apolipoprotein L1 (APOL1) gene mutations. The measure would designate the last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
This measure would encourage each individual in the United States to become better informed and aware of kidney disease and APOL1-mediated kidney disease (AMKD). The measure would encourage people from or with ancestry from Western and Central Africa to consider genetic testing for apolipoprotein L1 (APOL1) gene mutations. The measure would designate the third last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
This measure would encourage each individual in the United States to become better informed and aware of kidney disease and APOL1-mediated kidney disease (AMKD). The measure would encourage people from or with ancestry from Western and Central Africa to consider genetic testing for apolipoprotein L1 (APOL1) gene mutations. The measure would designate the third Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
WHEREAS, Kidney disease affects an estimated 37,000,000 Americans, and more than 550,000 are on dialysis; and
WHEREAS, Black people with kidney disease are more likely to develop kidney failure than any other racial or ethnic group; and
WHEREAS, The health disparities in kidney failure are unsustainable, with Black people making up to 13 percent of the United States population but accounting for 35 percent of those with kidney failure; and
WHEREAS, Kidney failure places enormous physical, emotional, and financial burdens on individuals and costs the Medicare program over $50 billion annually; and
WHEREAS, There are genetic factors that can increase an individuals risk for kidney disease; and
WHEREAS, One such genetic factor is having variants (mutations) in the apolipoprotein L1 (APOL1) gene; and
WHEREAS, People are more likely to have APOL1 gene variants if they are from Western or Central Africa or have an ancestor who came from these regions; and
WHEREAS, These variants can increase susceptibility for APOL1-mediated kidney disease (AMKD), a rapidly progressive form of kidney disease that can lead to kidney failure; and
WHEREAS, It is estimated that if a patient has variants in both copies of the APOL1 gene, there is a one in five chance they will go on to develop kidney disease, and an estimated 13 percent of Black Americans have variants in both copies of the APOL1 gene; and
WHEREAS, A person with AMKD may not have any symptoms of kidney disease until their kidneys are close to failing; and
WHEREAS, Genetic testing can reveal an individuals risk for AMKD, empowering them to take the steps necessary to protect their kidney health before it is too late; and
WHEREAS, Individuals who are found to have APOL1 genetic variants can reduce their risk for kidney failure by meeting with their doctor regularly, eating a healthy diet, taking all medications as prescribed, exercising for at least 30 minutes a day, and not smoking or using tobacco; and
WHEREAS, Additional awareness and research of APOL1 genetic mutations are needed to improve understanding of the kidney disease disparities in this population; and
WHEREAS, There are currently no FDA-approved treatments available for AMKD but clinical trials could provide an opportunity for researchers to develop and test safe treatments for AMKD; and
WHEREAS, The Governors office can raise public awareness of AMKD; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature encourages each individual in the United States to become better informed and aware of kidney disease and AMKD; and be it further
Resolved, That the Legislature encourages people from or with ancestry from Western and Central Africa to consider genetic testing for APOL1 gene mutations; and be it further
Resolved, That henceforth the Legislature designates the last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Kidney disease affects an estimated 37,000,000 Americans, and more than 550,000 are on dialysis; and
WHEREAS, Black people with kidney disease are more likely to develop kidney failure than any other racial or ethnic group; and
WHEREAS, The health disparities in kidney failure are unsustainable, with Black people making up to 13 percent of the United States population but accounting for 35 percent of those with kidney failure; and
WHEREAS, Kidney failure places enormous physical, emotional, and financial burdens on individuals and costs the Medicare program over $50 billion annually; and
WHEREAS, There are genetic factors that can increase an individuals risk for kidney disease; and
WHEREAS, One such genetic factor is having variants (mutations) in the apolipoprotein L1 (APOL1) gene; and
WHEREAS, People are more likely to have APOL1 gene variants if they are from Western or Central Africa or have an ancestor who came from these regions; and
WHEREAS, These variants can increase susceptibility for APOL1-mediated kidney disease (AMKD), a rapidly progressive form of kidney disease that can lead to kidney failure; and
WHEREAS, It is estimated that if a patient has variants in both copies of the APOL1 gene, there is a one in five chance they will go on to develop kidney disease, and an estimated 13 percent of Black Americans have variants in both copies of the APOL1 gene; and
WHEREAS, A person with AMKD may not have any symptoms of kidney disease until their kidneys are close to failing; and
WHEREAS, Genetic testing can reveal an individuals risk for AMKD, empowering them to take the steps necessary to protect their kidney health before it is too late; and
WHEREAS, Individuals who are found to have APOL1 genetic variants can reduce their risk for kidney failure by meeting with their doctor regularly, eating a healthy diet, taking all medications as prescribed, exercising for at least 30 minutes a day, and not smoking or using tobacco; and
WHEREAS, Additional awareness and research of APOL1 genetic mutations are needed to improve understanding of the kidney disease disparities in this population; and
WHEREAS, There are currently no FDA-approved treatments available for AMKD but clinical trials could provide an opportunity for researchers to develop and test safe treatments for AMKD; and
WHEREAS, The Governors office can raise public awareness of AMKD; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature encourages each individual in the United States to become better informed and aware of kidney disease and AMKD; and be it further
Resolved, That the Legislature encourages people from or with ancestry from Western and Central Africa to consider genetic testing for APOL1 gene mutations; and be it further
Resolved, That henceforth the Legislature designates the last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Kidney disease affects an estimated 37,000,000 Americans, and more than 550,000 are on dialysis; and
WHEREAS, Black people with kidney disease are more likely to develop kidney failure than any other racial or ethnic group; and
WHEREAS, The health disparities in kidney failure are unsustainable, with Black people making up to 13 percent of the United States population but accounting for 35 percent of those with kidney failure; and
WHEREAS, Kidney failure places enormous physical, emotional, and financial burdens on individuals and costs the Medicare program over $50 billion annually; and
WHEREAS, There are genetic factors that can increase an individuals risk for kidney disease; and
WHEREAS, One such genetic factor is having variants (mutations) in the apolipoprotein L1 (APOL1) gene; and
WHEREAS, People are more likely to have APOL1 gene variants if they are from Western or Central Africa or have an ancestor who came from these regions; and
WHEREAS, These variants can increase susceptibility for APOL1-mediated kidney disease (AMKD), a rapidly progressive form of kidney disease that can lead to kidney failure; and
WHEREAS, It is estimated that if a patient has variants in both copies of the APOL1 gene, there is a one in five chance they will go on to develop kidney disease, and an estimated 13 percent of Black Americans have variants in both copies of the APOL1 gene; and
WHEREAS, A person with AMKD may not have any symptoms of kidney disease until their kidneys are close to failing; and
WHEREAS, Genetic testing can reveal an individuals risk for AMKD, empowering them to take the steps necessary to protect their kidney health before it is too late; and
WHEREAS, Individuals who are found to have APOL1 genetic variants can reduce their risk for kidney failure by meeting with their doctor regularly, eating a healthy diet, taking all medications as prescribed, exercising for at least 30 minutes a day, and not smoking or using tobacco; and
WHEREAS, Additional awareness and research of APOL1 genetic mutations are needed to improve understanding of the kidney disease disparities in this population; and
WHEREAS, There are currently no FDA-approved treatments available for AMKD but clinical trials could provide an opportunity for researchers to develop and test safe treatments for AMKD; and
WHEREAS, The Governors office can raise public awareness of AMKD; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature encourages each individual in the United States to become better informed and aware of kidney disease and AMKD; and be it further
Resolved, That the Legislature encourages people from or with ancestry from Western and Central Africa to consider genetic testing for APOL1 gene mutations; and be it further
Resolved, That henceforth the Legislature designates the third last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Kidney disease affects an estimated 37,000,000 Americans, and more than 550,000 are on dialysis; and
WHEREAS, Black people with kidney disease are more likely to develop kidney failure than any other racial or ethnic group; and
WHEREAS, The health disparities in kidney failure are unsustainable, with Black people making up to 13 percent of the United States population but accounting for 35 percent of those with kidney failure; and
WHEREAS, Kidney failure places enormous physical, emotional, and financial burdens on individuals and costs the Medicare program over $50 billion annually; and
WHEREAS, There are genetic factors that can increase an individuals risk for kidney disease; and
WHEREAS, One such genetic factor is having variants (mutations) in the apolipoprotein L1 (APOL1) gene; and
WHEREAS, People are more likely to have APOL1 gene variants if they are from Western or Central Africa or have an ancestor who came from these regions; and
WHEREAS, These variants can increase susceptibility for APOL1-mediated kidney disease (AMKD), a rapidly progressive form of kidney disease that can lead to kidney failure; and
WHEREAS, It is estimated that if a patient has variants in both copies of the APOL1 gene, there is a one in five chance they will go on to develop kidney disease, and an estimated 13 percent of Black Americans have variants in both copies of the APOL1 gene; and
WHEREAS, A person with AMKD may not have any symptoms of kidney disease until their kidneys are close to failing; and
WHEREAS, Genetic testing can reveal an individuals risk for AMKD, empowering them to take the steps necessary to protect their kidney health before it is too late; and
WHEREAS, Individuals who are found to have APOL1 genetic variants can reduce their risk for kidney failure by meeting with their doctor regularly, eating a healthy diet, taking all medications as prescribed, exercising for at least 30 minutes a day, and not smoking or using tobacco; and
WHEREAS, Additional awareness and research of APOL1 genetic mutations are needed to improve understanding of the kidney disease disparities in this population; and
WHEREAS, There are currently no FDA-approved treatments available for AMKD but clinical trials could provide an opportunity for researchers to develop and test safe treatments for AMKD; and
WHEREAS, The Governors office can raise public awareness of AMKD; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature encourages each individual in the United States to become better informed and aware of kidney disease and AMKD; and be it further
Resolved, That the Legislature encourages people from or with ancestry from Western and Central Africa to consider genetic testing for APOL1 gene mutations; and be it further
Resolved, That henceforth the Legislature designates the third Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
|
Date
|
Status
|
|---|---|
| May 30, 2024 | Chaptered by Secretary of State - Res. Chapter 71, Statutes of 2024. |
| May 30, 2024 | Enrolled and filed with the Secretary of State at 3 p.m. |
| May 24, 2024 | In Assembly. Ordered to Engrossing and Enrolling. |
| May 23, 2024 | Adopted and to Assembly. (Ayes 37. Noes 0. Page 4184.) |
| May 21, 2024 | Ordered to special consent calendar. |
| May 8, 2024 | From committee: Ordered to third reading. |
| Apr 30, 2024 | In Senate. To Com. on RLS. |
| Apr 25, 2024 | Adopted and to Senate. (Ayes 75. Noes 0. Page 5001.) |
| Apr 25, 2024 | Coauthors revised. |
| Apr 22, 2024 | From committee: Be adopted. To Consent Calendar. (Ayes 7. Noes 0.) (April 22). |
| Apr 17, 2024 | Re-referred to Com. on RLS. |
| Apr 16, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on RLS. Amended. |
| Apr 15, 2024 | Referred to Com. on RLS. |
| Apr 10, 2024 | From printer. |
| Apr 9, 2024 | Introduced. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| May 23, 2024 | Special Consent ACR173 Bains et al. | Senate Floor |
Passed |
|
| Apr 25, 2024 | ACR 173 Bains Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Apr 22, 2024 | Be adopted. To Consent Calendar. | Assembly Standing Committee on Rules |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | ACR 173 |
THIRD READING
Bill No: ACR 173
Author: Bains (D), et al.
Amended: 4/16/24 in Assembly
Vote: 21
ASSEMBLY FLOOR: 75-0, 4/25/24 (Consent) - See last page for vote
SUBJECT: APOL1-Mediated Kidney Disease (AMKD) Awareness Day
SOURCE: Author
DIGEST:
This resolution (1) encourages each individual in the United States to become better informed and aware of kidney disease and APOL1-mediated kidney disease (AMKD); (2) encourage people from or with ancestry from Western and Central Africa to consider genetic testing for apolipoprotein L1 (APOL1) gene mutations; and (3) designates the last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
ANALYSIS: This resolution makes the following legislative findings:
- Kidney disease affects an estimated 37,000,000 Americans, and more than 550,000 are on dialysis; and
- There are genetic factors that can increase an individual’s risk for kidney disease. One such genetic factor is having variants (mutations) in the apolipoprotein L1 (APOL1) gene. People are more likely to have APOL1 gene variants if they are from Western or Central Africa or have an ancestor who came from these regions.
- These variants can increase susceptibility for APOL1-mediated kidney disease (AMKD), a rapidly progressive form of kidney disease that can lead to kidney failure. Genetic testing can reveal an individual’s risk for AMKD, empowering them to take the steps necessary to protect their kidney health before it is too late.
- Additional awareness and research of APOL1 genetic mutations are needed to improve understanding of the kidney disease disparities in this population. There are currently no FDA-approved treatments available for AMKD but clinical trials could provide an opportunity for researchers to develop and test safe treatments for AMKD.
This resolution:
- Encourages people from or with ancestry from Western and Central Africa to consider genetic testing for APOL1 gene mutations.
- Designates the last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
Comments
According to the author, “Kidney Disease affects 37 million Americans, with 550,000 patients on dialysis. ACr 173 encourages Californians to become better aware of kidney disease and AMKD. It also encourages Californians with West and Central African ancestry to consider genetic testing for APOL1.”
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 5/7/24)
None received
OPPOSITION: (Verified 5/7/24)
None received
ASSEMBLY FLOOR: 75-0, 4/25/24
AYES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Chen, Connolly, Davies, Dixon, Essayli, Flora, Mike Fong, Vince Fong, Friedman, Gabriel, Garcia, Gipson, Grayson, Haney, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Luz Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO VOTE RECORDED: Boerner, Megan Dahle, Gallagher, Hart, Mathis
Prepared by: Russell Manning / SFA / (916) 651-1520
5/8/24 13:47:34
**** END ****
Date of Hearing: April 22, 2024
ASSEMBLY COMMITTEE ON RULES
Blanca Pacheco, Chair
ABPCA Bill Id:ACR 173 (
Author:Bains) – As Amended Ver:April 16, 2024
SUBJECT: APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
SUMMARY: Designates the last Tuesday of every April as APOL1-Mediated Kidney Disease (AMKD) Awareness Day, and encourages each individual in the United States to become better informed and aware of kidney disease and AMKD. Specifically, this resolution makes the following legislative findings:
- Kidney disease affects an estimated 37 million Americans, and more than 550,000 are on dialysis. Black people with kidney disease are more likely to develop kidney failure than any other racial or ethnic group.
- The health disparities in kidney failure are unsustainable, with Black people making up to 13 percent of the United States population but accounting for 35 percent of those with kidney failure.
- Kidney failure places enormous physical, emotional, and financial burdens on individuals and costs the Medicare program over $50 billion annually.
- There are genetic factors that can increase an individual’s risk for kidney disease. One such genetic factor is having variants (mutations) in the apolipoprotein L1 (APOL1) gene. People are more likely to have APOL1 gene variants if they are from Western or Central Africa or have an ancestor who came from these regions.
- It is estimated that if a patient has variants in both copies of the APOL1 gene, there is a one in five chance they will go on to develop kidney disease, and an estimated 13 percent of Black Americans have variants in both copies of the APOL1 gene.
- Genetic testing can reveal an individual’s risk for AMKD, empowering them to take the steps necessary to protect their kidney health before it is too late. Individuals who are found to have APOL1 genetic variants can reduce their risk for kidney failure by meeting with their doctor regularly, eating a healthy diet, taking all medications as prescribed, exercising for at least 30 minutes a day, and not smoking or using tobacco.
- Additional awareness and research of APOL1 genetic mutations are needed to improve understanding of the kidney disease disparities in this population. There are currently no FDA-approved treatments available for AMKD but clinical trials could provide an opportunity for researchers to develop and test safe treatments for AMKD.
FISCAL EFFECT: None
REGISTERED SUPPORT / OPPOSITION:
Support
None on file
Opposition
None on file
Analysis Prepared by: Michael Erke / RLS. / (916) 319-2800
Bill Author
Bill Co-Author(s):